Related Experiment Video
Updated: May 11, 2026
07:30
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Calcium channel blockers and dementia.
1Neuroscience Research, GPRD, AbbVie GmbH, Ludwigshafen, Germany. volker.nimmrich@abbott.com
British Journal of Pharmacology
|May 4, 2013
Summary
Calcium channel blockers show promise for treating degenerative dementia by protecting neurons in Alzheimer's and vascular dementia. Further research focuses on optimizing these blockers for improved efficacy and neuronal protection.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Degenerative dementia, including Alzheimer's disease and vascular dementia, is linked to disrupted intracellular calcium homeostasis.
- Amyloid-beta accumulation in Alzheimer's disease may increase neuronal calcium load, causing excitotoxicity.
- Cerebral hypoperfusion underlies vascular dementia, potentially benefiting from vasodilation via calcium channel blockers.
Purpose of the Study:
- To explore the role of calcium channel blockers in mitigating neurodegeneration in Alzheimer's disease and vascular dementia.
- To review the efficacy of existing calcium channel blockers in clinical dementia trials.
- To identify strategies for optimizing calcium channel blockers for enhanced neuroprotection.
Main Methods:
- Review of in vitro and animal model studies on calcium channel blockade and amyloid-beta-induced neurodegeneration.
- Analysis of clinical trial data for various calcium channel blockers in dementia treatment.
- Discussion of potential mechanisms of action, including direct neuronal protection and vasodilation.
Main Results:
- Calcium channel blockade demonstrated neuroprotective effects against amyloid-beta in preclinical studies.
- Clinical trials yielded heterogeneous results, with some calcium channel blockers (nimodipine, nilvadipine) showing cognitive benefits.
- Positive outcomes in trials suggest a direct neuroprotective effect independent of blood pressure reduction.
Conclusions:
- Calcium channel blockers hold therapeutic potential for degenerative dementias.
- Optimizing blockers for presynaptic calcium channel selectivity and affinity to inactivated states is crucial.
- Novel compounds are available for further proof-of-concept studies in dementia treatment.
Related Concept Videos
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.